288 related articles for article (PubMed ID: 17047071)
1. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
2. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
5. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
9. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
[TBL] [Abstract][Full Text] [Related]
13. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
14. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
Moase EH; Qi W; Ishida T; Gabos Z; Longenecker BM; Zimmermann GL; Ding L; Krantz M; Allen TM
Biochim Biophys Acta; 2001 Feb; 1510(1-2):43-55. PubMed ID: 11342146
[TBL] [Abstract][Full Text] [Related]
15. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
17. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
18. Liposome-mediated therapy of neuroblastoma.
Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
[TBL] [Abstract][Full Text] [Related]
19. Targeting Stealth liposomes in a murine model of human small cell lung cancer.
Moreira JN; Gaspar R; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):167-76. PubMed ID: 11718672
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
